1. Technical Field
The present disclosure relates generally to packaging for medical devices, and more particularly, to a medical device package including a container having an area configured to receive a medical device and an area configured for storing at least one agent and a port for permitting the passage of a contact material between the outside of the container and the area of the container configured for storing the agent.
2. Background of Related Art
Combination medical devices, i.e., medical devices coated with drugs or other bioactive agents, have become more prevalent commercially in recent years. There are many of these combination medical devices known to those skilled in the art. Many of these devices require specialized coatings to facilitate both bioactive agent elution and, more importantly, maintain or enhance the core functionality of the medical device. For example, a suture containing an antimicrobial coating must be able to facilitate the elution of the antimicrobial agent in the coating and also maintain a certain tensile strength, handling ability, knot-tying ability, and degradation rate to ensure the coated suture remains functional as a wound closure device.
Further, with the selection of a new coating, drug or any combination of medical devices comes the challenge of marrying the selected agents with a coating or medical device that can accommodate both technical requirements described above, as well as the manufacturing, sterilizing, and transporting processes involved in producing such products. This often requires the design of new coating polymers, which are specialized to be compatible with a specific agent, as well as new coating, manufacturing, sterilizing and transporting processes. In addition, designing these new coatings and processes creates the added pressures of possibly impacting the shelf-life of the device as well as the end-use of the combination medical device in a negative manner.
Also, medical professionals are limited to using the combination medical device in the dosage and strength produced, without flexibility to alter the product as needed for their respective patients.
Therefore, the present disclosure describes a package for a medical device aimed at simplifying the design and application of combination medical device coatings to provide the following benefits: sensitive agents can be delivered without compromising standard storage or transport conditions; the ability to later combine a specific medical device with agents that were unable to tolerate the required sterilization process for that specific device, under sterile conditions; the medical professional has greater control over product selection; and longer shelf-life of products due to more stable format.
Accordingly, a package for a medical device in accordance with the present disclosure includes a container for receiving a medical device wherein the container has an area configured for storing at least one agent and a port for permitting the passage of a contact material between the outside of the container and the area of the container configured for storing at least one agent therein. The area configured for storing the agent may be defined within the container or as a separate compartment positioned within or adjacent to the container.
In another embodiment, a medical device package as described herein may include a container configured for receiving a medical device including a reservoir for storing at least one agent and a port for permitting the passage of a contact material between the outside of the container and the reservoir configured for storing the agent. The reservoir is positioned within the container in a manner capable of applying the agent to at least a portion of the medical device received in the container. The portion of the medical device to be contacted by the agent and/or the contact material may pass through or be positioned within the reservoir.
In still another embodiment, a medical device package in accordance with the present disclosure includes a container for receiving a medical device having at least one separate, self-contained agent and a port for permitting the passage of a contact material between the outside of the container and the self-contained agent. It is envisioned that the contact material will interact with the self-contained agent in any manner suitable for activating and/or releasing the agent stored therein so that the medical device received by the container may come in contact with the agent and/or the contact material.
Various embodiments are described herein with reference to the drawings wherein:
The medical device packages described herein include a container having an area configured for receiving a medical device, an area configured for storing at least one agent and a port for permitting the passage of a contact material between the outside of the container and the area configured for storing at least one agent. In some embodiments, the container may include a single area configured for receiving both the medical device and the agent.
It is envisioned that any medical device may be stored within the package. Some examples include, but are not limited to, sutures, staples, clips, adhesives, sealants, stents, grafts, meshes, sternum closures, pins, screws, tacks, and adhesion barriers.
The container is dimensioned and configured to receive a medical device. The container may be any conventional enclosure for storing medical devices and more than one container may be combined to form the medical device packages described herein. Some examples of useful containers include, but are not limited too, pouches, paper retainers, plastic retainers, bags, trays, envelopes, Tyvek® bags, foil-packs, and the like. It is envisioned that the containers may be sealable, non-sealable, breathable, non-breathable, peelable, resealable, and combinations thereof.
The container may be manufactured from any material known to those skilled in the art which is suitable for receiving or storing a medical device. Some examples of suitable materials include, but are not limited to, polycarbonate, high-density polyethylene, polyethylene, polypropylene, thermoplastic resins, polytetrafluoroethylene, ε-caprolactone, glycolide, 1-lactide, d,1-lactide, d-lactide, meso-lactide, trimethylene carbonate, 4,4-dimethyl-1,3-dioxan-2-one, p-dioxanone, dioxepanone, δ-valerolactone, β-butyrolactone, ε-decalactone, 2,5-diketomorpholine, pivalolactone, α,α-diethylpropiolactone, 6,8-dioxabicyclooctan-7-one, ethylene carbonate, ethylene oxalate, 3-methyl-1,4-dioxane-2,5-dione, 3,3-dimethyl-1,4-dioxane-2,5-dione, polyolefins, polysiloxanes, polyalkylene glycols, polyacrylates, aminoalkyl acrylates, polyvinylalcohols, polyvinylpyrrolidones, polyoxyethylenes, polyacrylamides, poly(2-hydroxyethylmethacrylate), polymethacrylamide, dextran, alginic acid, sodium alginate, polysaccharides, gelatin and copolymers, homopolymers, and block copolymers thereof.
As further described herein, the container includes an area configured for storing at least one agent. The area for storing the agent is positioned within or adjacent to the package and/or the container in a manner which allows the agent to interact with at least a portion of the medical device. It is envisioned that the agent or agents may be stored in the area configured for storing the agent at any time between the manufacturing of the package and the end-use or withdrawal of the medical device. In some embodiments, the area configured for storing the agent may be intended to keep the agent from prematurely reacting with the medical device prior to use by medical personnel or the introduction of the contact material via the port.
In some embodiments, the area configured for storing the agent may be defined within the container (See
The area configured for storing the agent is capable of storing the agent in any suitable form. The agent may be stored as solid, liquid, semi-solid, gas, or any combination thereof. The at least one agent may be selected from any bioactive and/or non-bioactive agent suitable for combination with the medical device. Suitable agents include, but are not limited to, drugs, such as antiseptics, anesthetics, muscle relaxants, antihistamines, decongestants, antimicrobial agents, anti-viral agents, anti-fungal agents, antimalarials, amebicides, antituberculosal agents, antiretroviral agents, leprostatics, antiprotazoals, antihelmitics, antibacterial agents, steroids, hematopoietic agents, antiplatelet agents, anticoagulants, coagulants, thrombolytic agents, hemorrheologic agents, hemostatics, plasma expanders, hormones, sex hormones, uterine-active agents, bisphosphonates, antidiabetic agents, glucose-elevating agents, growth hormones, thyroid hormones, inotropic agents, antiarrhythmic agents, calcium channel blockers, vasodilators, sympatholytics, antihyperlipidemic agents, vasopressors, angiotensin antagonists, sclerosing agents, anti-impotence agents, urinary alkanizers, urinary acidifiers, anticholinergics, diuretics, bronchodilators, surfactants, antidepressants, antipsychotics, antianxiety agents, sedatives, hypnotics, barbiturates, antiemetic agents, analgesics, stimulants, anticonvulsants, antiparkinson agents, proton pump inhibitors, H2-antagonists, antispasmodics, laxatives, antidiarrheals, antiflatulents, digestive enzymes, gallstone solubilizing agents, antihypertensive agents, cholesterol-lowering agents, radiopaque agents, immune globulins, monoclonal antibodies, antibodies, antitoxins, antivenins, immunologic agents, anti-inflammatory agents, antineoplastic agents, alkylating agents, antimetabolites, antimitotic agents, radiopharmaceuticals, vitamins, herbs, trace elements, amino acids, enzymes, chelating agents, immunomodulatory agents and immunosuppressive agents; coating materials such as lubricants, and non-bioabsorbable substances such as silicone, beeswax, or polytetrafluoroethylene, as well as absorbable substances such as collagen, chitosan, chitin, carboxymethylcellulose, and homopolymers and/or copolymers of polyalkylene glycols, and higher fatty acids or salts or esters thereof, glycolic acid, a glycolide, lactic acid, a lactide, p-dioxanone, valerolactone and other lactones derived from linear aliphatic hydroxycarboxylic acids, α-hydroxybutyric acid, ethylene carbonate, ethylene oxide, propylene oxide, propylene carbonate, malic acid ester lactones, succinic acid, adipic acid and other linear aliphatic dicarboxylic acids, and linear aliphatic diols such as butanediol and hexanediol; wound healing agents; adhesives; sealants; blood products; blood components; preservatives; colorants; dyes; ultraviolet absorbers; ultraviolet stabilizers; photochromic agents; anti-adhesives; proteins; polysaccharides; peptides; genetic material; viral vectors; nucleic acids; nucleotides; plasmids; lymphokines; radioactive agents; metals; alloys; salts; growth factors; growth factor antagonists; cells; hydrophobic agents; hydrophilic agents; immunological agents; anti-colonization agents; diagnostic agents; imaging agents; diluents, such as water, saline, dextrose; and combinations thereof.
In addition to the container and the area configured for storing at least one agent, the package includes a port. The port is designed to permit the passage of at least one diluent between the outside of the container and the area configured for storing the agent. It is envisioned that the port may be any type of port or hub, known to allow the passage of a diluent therethrough. The port may be made of any size, shape or dimension and may be composed of any rubber, gel, metallic, polymeric, or thermoplastic material known to those skilled in the art. The port may also be sealable, non-sealable, resealable, stationary, movable, peelable, self-puncturable and combinations thereof.
The port may be positioned along any side, edge or corner of the container. In embodiments wherein the package includes more than one container, the port may be positioned along any side, edge or corner of any of the containers included in the package. In addition, the package may contain more than one port and/or more than container may share a common port.
In some embodiments, the port may be an injectable-hub, or injection port, which is designed to remain sealed by self-sealing action to ensure no liquid, semi-solid, or gas medium can escape and also so no pathogens can breach the container. In some embodiments, the port may be a hub designed in such a way that only a particular injector can mate with the port, i.e., male/female or lock/key type hubs. These types of ports provide more safety to the user of the port because the port does not necessarily require the use of a sharp injector or needle.
The contact material is intended to be delivered from outside the container, via the port, to the area configured for storing at least one agent. In embodiments where the container includes at least one agent, the contact material may be introduced to initiate or enhance the interaction, penetration, impregnation, or coating of the medical device by the stored agent. The term “contact material” is meant to include any material, i.e., solid, liquid, semi-solid, gas, or combination thereof which interacts with the agent, the medical device, or the container itself. In some embodiments, the contact material may be any of the bioactive or non-bioactive agents described herein. In particularly useful embodiments, contact materials include diluents or wetting agents, such as water, saline, dextrose and lactated ringers.
Turning now to
In another embodiment, as shown in
It is also envisioned that the reservoir may be detachable or removable from container 20. It is envisioned that the reservoir is capable of storing from about 0.01 microliters to about 10,000 microliters. In some embodiments, the reservoir 40 does not contain an agent. Rather, an agent or a contact material or both may be added to reservoir 40 via port 60 by the end-user of the medical device immediately prior to withdrawal of the medical device.
Turning now to
It is well understood that various modifications may be made to the embodiments disclosed herein. Therefore, the above description should not be construed as limiting, but merely as exemplifications of particularly useful embodiments. Those skilled in the art will envision other modifications within the scope and spirit of the claims appended hereto.
This application is a divisional of U.S. application Ser. No. 11/544,503 filed Oct. 6, 2006 now abandoned and the disclosures of each of the above-identified applications are hereby incorporated by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
3369708 | Hein | Feb 1968 | A |
4259184 | D'Arnal | Mar 1981 | A |
4366901 | Short | Jan 1983 | A |
4424898 | Thyen et al. | Jan 1984 | A |
4699271 | Lincoln et al. | Oct 1987 | A |
4896767 | Pinheiro | Jan 1990 | A |
4961498 | Kalinski et al. | Oct 1990 | A |
4967902 | Sobel et al. | Nov 1990 | A |
5024322 | Holzwarth | Jun 1991 | A |
5038938 | Berndt | Aug 1991 | A |
5052551 | Cerwin et al. | Oct 1991 | A |
5056658 | Sobel et al. | Oct 1991 | A |
5099994 | Kalinski et al. | Mar 1992 | A |
5131533 | Alpern | Jul 1992 | A |
5165217 | Sobel et al. | Nov 1992 | A |
5179818 | Kalinski et al. | Jan 1993 | A |
5180053 | Cascio et al. | Jan 1993 | A |
5192483 | Kilgrow et al. | Mar 1993 | A |
5213210 | Cascio et al. | May 1993 | A |
5222978 | Kaplan et al. | Jun 1993 | A |
5228565 | Sinn | Jul 1993 | A |
5230424 | Alpern et al. | Jul 1993 | A |
5236083 | Sobel et al. | Aug 1993 | A |
5246104 | Brown et al. | Sep 1993 | A |
5249671 | Sinn | Oct 1993 | A |
5249673 | Sinn | Oct 1993 | A |
5263585 | Lawhon et al. | Nov 1993 | A |
5271495 | Alpern | Dec 1993 | A |
5275185 | Florjancic | Jan 1994 | A |
5284240 | Alpern et al. | Feb 1994 | A |
5350060 | Alpern et al. | Sep 1994 | A |
5359831 | Brown et al. | Nov 1994 | A |
5366081 | Kaplan et al. | Nov 1994 | A |
5407071 | Lawhon et al. | Apr 1995 | A |
5417036 | Brown et al. | May 1995 | A |
5433315 | Brandau | Jul 1995 | A |
5462162 | Kaplan et al. | Oct 1995 | A |
5468252 | Kaplan et al. | Nov 1995 | A |
5472081 | Kilgrow et al. | Dec 1995 | A |
5503266 | Kalbfeld et al. | Apr 1996 | A |
5575382 | Sobel et al. | Nov 1996 | A |
5628395 | Daniele et al. | May 1997 | A |
5655652 | Sobel et al. | Aug 1997 | A |
5669490 | Colligan et al. | Sep 1997 | A |
5675961 | Cerwin et al. | Oct 1997 | A |
5681740 | Messier et al. | Oct 1997 | A |
5698210 | Levy | Dec 1997 | A |
5704469 | Daniele et al. | Jan 1998 | A |
5733293 | Scirica et al. | Mar 1998 | A |
5788062 | Cerwin et al. | Aug 1998 | A |
5887706 | Pohle et al. | Mar 1999 | A |
5906273 | Pohle et al. | May 1999 | A |
5918733 | Cerwin et al. | Jul 1999 | A |
5954748 | Totakura | Sep 1999 | A |
6016905 | Gema et al. | Jan 2000 | A |
6047815 | Cerwin et al. | Apr 2000 | A |
6076659 | Baumgartner et al. | Jun 2000 | A |
6098796 | Januzeli et al. | Aug 2000 | A |
6105339 | Pohle et al. | Aug 2000 | A |
6135272 | Sobel et al. | Oct 2000 | A |
6135385 | Martinez de Lahidalga | Oct 2000 | A |
6138440 | Gemma | Oct 2000 | A |
6260699 | Kaplan et al. | Jul 2001 | B1 |
6394269 | Rudnick et al. | May 2002 | B1 |
6443949 | Altman | Sep 2002 | B2 |
6464071 | Baumgartner | Oct 2002 | B2 |
6481568 | Cerwin et al. | Nov 2002 | B1 |
6481569 | Alpern | Nov 2002 | B1 |
6533112 | Warnecke | Mar 2003 | B2 |
6644469 | Alpern | Nov 2003 | B2 |
6648133 | Blaschke et al. | Nov 2003 | B1 |
6807737 | Davia | Oct 2004 | B1 |
20030198666 | Abbas et al. | Oct 2003 | A1 |
20050167309 | Iwatschenko | Aug 2005 | A1 |
20050278012 | Vonderwalde | Dec 2005 | A1 |
20060027467 | Ferguson | Feb 2006 | A1 |
20060029722 | Larson et al. | Feb 2006 | A1 |
20060069018 | Sakai et al. | Mar 2006 | A1 |
20060163752 | Wang et al. | Jul 2006 | A1 |
20060193884 | Stopek et al. | Aug 2006 | A1 |
Number | Date | Country |
---|---|---|
4323266 | Jan 1994 | DE |
0 418 059 | Mar 1991 | EP |
0 558 085 | Sep 1993 | EP |
0 558 086 | Sep 1993 | EP |
0 564 274 | Oct 1993 | EP |
0 726 062 | Aug 1996 | EP |
0 728 445 | Aug 1996 | EP |
1 275 343 | Jan 2003 | EP |
1 312 556 | May 2003 | EP |
1 316 291 | Jun 2003 | EP |
1 327 865 | Aug 1973 | GB |
WO 9811932 | Mar 1998 | WO |
WO 9937233 | Jul 1999 | WO |
WO 0136289 | May 2001 | WO |
WO 03008285 | Jan 2003 | WO |
WO 03092779 | Nov 2003 | WO |
WO 03101334 | Dec 2003 | WO |
Entry |
---|
International Search Report EP 07253902. |
International Search Report PCT/US08/002458. |
International Search Report PCT/US08/002457. |
International Search Report PCT/US07/021421 dated Feb. 26, 2008 (10 pages). |
Number | Date | Country | |
---|---|---|---|
20100116694 A1 | May 2010 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11544503 | Oct 2006 | US |
Child | 12544444 | US |